Blockchain Registration Transaction Record

Glafabra Therapeutics Secures Exclusive Rights to Innovative Lentivector Technology for Enhanced Gene Therapy

Glafabra Therapeutics secures exclusive rights to innovative lentivector technology from Medical College of Wisconsin, enhancing gene therapy for enzyme deficiency diseases. Patients report remarkable health improvements with Glafabra's LV gene therapy for Fabry disease, signaling a promising future for advanced medical solutions.

Glafabra Therapeutics Secures Exclusive Rights to Innovative Lentivector Technology for Enhanced Gene Therapy

This news highlights a significant advancement in gene therapy technology that could revolutionize the treatment of enzyme deficiency diseases, offering new hope to patients worldwide. Glafabra's commitment to innovation and expansion into the US market signifies a major step forward in providing effective and durable therapies for individuals in need.

BlockchainDetails
Contract Address0x0553B273B8eBf464Bd2a37C259F0eEBb3d70Fd71
Transaction ID0x170c469390f81b3c884bb428092f3863d9c96d6c4ece7a1766ee6ce065fb1a72
Account0xdBdE7c76e403a5923F3dD4F050Dbbf5c2077BB20
Chainpolygon-main
NewsRamp Digital FingerprintninaRFS5-f5a64068fa883773ed2d81f41c28d6f9